Arpeat Kaviya

500 total citations
11 papers, 386 citations indexed

About

Arpeat Kaviya is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Arpeat Kaviya has authored 11 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Arpeat Kaviya's work include Inflammatory Bowel Disease (8 papers), Microscopic Colitis (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Arpeat Kaviya is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Microscopic Colitis (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Arpeat Kaviya collaborates with scholars based in United Kingdom, United States and Canada. Arpeat Kaviya's co-authors include Brian G. Feagan, Silvio Danese, David T. Rubin, Edward V. Loftus, Ira Shafran, Séverine Vermeire, Geert D’Haens, Jean‐Frédéric Colombel, Remo Panaccione and William J. Sandborn and has published in prestigious journals such as Gastroenterology, Inflammatory Bowel Diseases and Value in Health.

In The Last Decade

Arpeat Kaviya

10 papers receiving 378 citations

Peers

Arpeat Kaviya

GENET

EPIDE

IMMUN

SURGE

PHEOH

Pauline Wils France

Siddharth Bhatia India

Katrien Asnong Belgium

Mathurin Flamant France

Phillip Minar United States

Hélène Pillant France

Ann Gils Belgium

Sophie Tops Belgium

Janelle Laskowski United States

Edouard Louis Belgium

Pauline Wils France

Arpeat Kaviya

353 ×1.0

GENET

276 ×1.0

EPIDE

111 ×0.8

IMMUN

123 ×1.3

SURGE

16 ×0.4

PHEOH

Citations per year, relative to Arpeat Kaviya Arpeat Kaviya (= 1×) peers Pauline Wils

Countries citing papers authored by Arpeat Kaviya

Since Specialization

Citations

This map shows the geographic impact of Arpeat Kaviya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arpeat Kaviya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arpeat Kaviya more than expected).

Fields of papers citing papers by Arpeat Kaviya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arpeat Kaviya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arpeat Kaviya. The network helps show where Arpeat Kaviya may publish in the future.

Co-authorship network of co-authors of Arpeat Kaviya

This figure shows the co-authorship network connecting the top 25 collaborators of Arpeat Kaviya. A scholar is included among the top collaborators of Arpeat Kaviya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arpeat Kaviya. Arpeat Kaviya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Kaviya, Arpeat, et al.. (2019). SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations

Castellani, Carlo, Carla Colombo, Cornelis K. van der Ent, et al.. (2018). An Observational Study of Ivacaftor in Patients with Cystic Fibrosis and Selected Non-G551D Gating Mutations in UK, Italy and Netherlands: Healthcare Resource Utilization from the First Interim Analysis of the Vocal Study. Value in Health. 21. S255–S255. 1 indexed citations

Feagan, Brian G., Stefan Schreiber, Douglas C. Wolf, et al.. (2018). Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases. 25(6). 1028–1035. 21 indexed citations

Castellani, Carlo, et al.. (2018). WS05.4 Clinical effectiveness results from the first interim analysis of the VOCAL study; an observational study of ivacaftor in patients with cystic fibrosis and selected non-G551D gating mutations. Journal of Cystic Fibrosis. 17. S10–S10. 3 indexed citations

Vermeire, Séverine, Edward V. Loftus, J F Colombel, et al.. (2017). DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. Journal of Crohn s and Colitis. 11(suppl_1). S39–S39. 3 indexed citations

Vermeire, Séverine, Edward V. Loftus, Jean‐Frédéric Colombel, et al.. (2017). Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study. Gastroenterology. 152(5). S601–S601. 9 indexed citations

Loftus, Edward V., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2017). P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. Journal of Crohn s and Colitis. 11(suppl_1). S182–S183. 4 indexed citations

Stallmach, Andreas, Bernd Bokemeyer, Jeffrey Axler, et al.. (2017). DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters. Journal of Crohn s and Colitis. 11(suppl_1). S42–S43. 1 indexed citations

Loftus, Edward V., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2017). Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. Gastroenterology. 152(5). S602–S602. 8 indexed citations

10.

Loftus, Edward V., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2016). Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn s and Colitis. 11(4). jjw177–jjw177. 167 indexed citations

11.

Vermeire, Séverine, Edward V. Loftus, Jean‐Frédéric Colombel, et al.. (2016). Long-term Efficacy of Vedolizumab for Crohn’s Disease. Journal of Crohn s and Colitis. 11(4). jjw176–jjw176. 168 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact